Yeh, Tzu-min
Medical College of Wisconsin · Josep Carreras Leukaemia Research Institute · Hospital Clínic de Barcelona · Instituto de Investigación Biomédica de Salamanca · Clinica Universidad de Navarra · Centro de Investigación Biomédica en Red de Cáncer · Centro de Investigación Médica Aplicada · Janssen Research & Development (United States) · University College London · Universitat de Barcelona
5 papers on CoChat
Most cited papers
- Verified
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 1,756
- Verified
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine
Multiple Myeloma Research and TreatmentsCAR-T cell therapy research
Cited by 827
- Verified
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 663
- Verified
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
Lin, Y., Martin, T. G., Usmani, S. Z., Berdeja, J. G., Jakubowiak, A. J., Agha, M. E., Cohen, A. D., Deol, A., Htut, M., Lesokhin, A. M., et al. (2023) · Journal of Clinical Oncology
Multiple Myeloma Research and TreatmentsCAR-T cell therapy research
Cited by 120
- Verified
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.
Einsele, H., Cohen, A. D., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., Schecter, J. M., De Braganca, K. C., et al. (2022) · Journal of Clinical Oncology
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free